As a British-Swiss public health physician and a Global Healthcare Investment Fellow at Goldman Sachs, I am committed to reducing health inequalities, enhancing access to care, and improving the quality of healthcare for patients and the population. I’m engaged in supporting populations to overcome the effects of COVID-19 as a research scientist at Cambridge University, where my research has focused on COVID-19 antibody detection and identifying COVID-19 vaccine and therapeutic trials.
I have worked to make healthcare proactive rather than reactive and bring healthcare to the point of care as a public health lead for the Fenland COVID-19 study at the MRC Epidemiology Unit - I have been investigating the use of Huma software for early COVID-19 detection and trialling a device that enables people to take blood samples at home without the need of a healthcare professional.
Passionate about innovation and having been a founder from the Cambridge Judge Business School accelerator, I mentor entrepreneurs and have supported founders as an Entrepreneur-in-Residence for healthcare focused venture capital firms. My work is now focused on driving the translation of technology into healthcare systems and investing in biotech, digital health, and medtech to provide enhanced patient-centred care.